Maribavir may reduce mortality risk among patients with resistant or refractory post-transplant CMV infection following hematopoietic stem cell and solid organ transplant.
New evidence points to a cycle wherein undifferentiated stem cells mature to perform hair coloring duties and transform back to their primitive form. To accomplish this, they need to stay on the move.